Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save

Next deadline: Oct 16, 2021

Later deadlines: Nov 16, 2021

Grant amount: Up to US $275,000

Fields of work: Cardiovascular Diseases & Systems Cancer/Oncology

Applicant type: Organizations

Funding uses: Biomedical, Behavioral

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought.

Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including:

  • Cytotoxic chemotherapies,
  • Targeted agents,
  • Immunomodulatory therapies and
  • Radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

This page was last reviewed December 19, 2018 and last updated December 19, 2018